We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

62 hedge funds and large institutions have $66.3M invested in Lineage Cell Therapeutics in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 11

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

15% more capital invested

Capital invested by funds: $57.6M → $66.3M (+$8.69M)

7% more funds holding

Funds holding: 58 → 62 (+4)

4.98% more ownership

Funds ownership: 32.33% → 37.31% (+5%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

98% less call options, than puts

Call options by funds: $4K | Put options by funds: $199K

Holders
62
Holders Change
+4
Holders Change %
+6.9%
% of All Funds
1.78%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
25
Reduced
11
Closed
6
Calls
$4K
Puts
$199K
Net Calls
-$195K
Net Calls Change
-$70K

Top Buyers

1
BC
Broadwood Capital
New York
+$10.1M
2
BFA
BlackRock Fund Advisors
California
+$556K
3
WSCM
Wellington Shields Capital Management
New York
+$410K
4
BIT
BlackRock Institutional Trust
California
+$286K
5
VKH
Virtu KCG Holdings
New York
+$133K

Top Sellers

1
CS
Credit Suisse
Switzerland
-$180K
2
Renaissance Technologies
Renaissance Technologies
New York
-$170K
3
Goldman Sachs
Goldman Sachs
New York
-$160K
4
Swiss National Bank
Swiss National Bank
Switzerland
-$93K
5
Deutsche Bank
Deutsche Bank
Germany
-$71.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
51
Wolverine Asset Management
Illinois
$7K +$6.44K +2,850 New
TRCT
52
Tower Research Capital (TRC)
New York
$6K -$1.22K -542 -19%
Deutsche Bank
53
Deutsche Bank
Germany
$5K -$71.7K -31,744 -94%
ARMC
54
American Research & Management Company
Massachusetts
$5K – – –
NFG
55
Next Financial Group
Texas
$5K +$4.76K +2,106 New
Citigroup
56
Citigroup
New York
$2K -$14.3K -6,320 -89%
TAM
57
Tocqueville Asset Management
New York
$2K – – –
VIA
58
Vantage Investment Advisors
Pennsylvania
$2K – – –
Creative Planning
59
Creative Planning
Kansas
$1K – – –
HF
60
Hoxton Financial
West Virginia
$1K – – –
Ameriprise
61
Ameriprise
Minnesota
$1K +$867 +384 New
Renaissance Technologies
62
Renaissance Technologies
New York
– -$170K -64,057 Closed
Swiss National Bank
63
Swiss National Bank
Switzerland
– -$93K -35,188 Closed
BJ
64
BlackRock Japan
Japan
– -$12K -4,387 Closed
Teacher Retirement System of Texas
65
Teacher Retirement System of Texas
Texas
– -$5K -1,707 Closed
BlackRock
66
BlackRock
New York
– -$4K -1,658 Closed
LTFS
67
Ladenburg Thalmann Financial Services
Florida
– -$1K -496 Closed
1 2
3

LCTX Hedge Fund Activity: Q2 2014 in Review

62 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2014, worth a combined $66.3M — up 15% from $57.6M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new LCTX positions and 6 closed out — a net gain of 4 holders — while 25 added to existing stakes and 11 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $10.1M. The largest seller was Credit Suisse, cutting an estimated $180K.

  • 62 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2014, up from 58 in Q1 2014.
  • Funds reported $66.3M of Lineage Cell Therapeutics stock for Q2 2014, up 15% quarter-over-quarter.
  • 10 funds opened new Lineage Cell Therapeutics positions in Q2 2014 and 6 closed out, a net change of +4 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2014 was Broadwood Capital, an estimated $10.1M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2014 was Credit Suisse, an estimated $180K sold.

Based on aggregated 13F filings for Q2 2014.